GlassScriptPhysician profile
Nicholas L Lillo
NPI 1871573683
$2,900.25
in general payments reported to CMS, 2019-2025
27 companies · $92.19 in 2025
The $92.19 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $691 · 2021: $682 · 2022: $133 · 2023: $172 · 2024: $19.68 · 2025: $92.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $497.05 | 2019-2023 | Trulance |
| Abbvie INC. | $419.99 | 2019-2025 | |
| Astellas Pharma US INC | $399.74 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.85 | 2019 | |
| Lupin INC. | $178.90 | 2019-2021 | |
| Exeltis, USA INC. | $175.84 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $167.40 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $143.34 | 2019-2020 | |
| Gilead Sciences, INC. | $124.16 | 2019-2021 | |
| Avion Pharmaceuticals | $76.98 | 2019-2021 | |
| Coopersurgical, INC. | $72.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.81 | 2019-2021 | |
| Ardelyx, INC. | $53.01 | 2022 | |
| Duchesnay USA Incorporated | $49.06 | 2019 | |
| Ferring Pharmaceuticals INC. | $46.82 | 2023 | Rebyota |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $43.18 | 2019 | |
| Braintree Laboratories, INC. | $28.78 | 2021 | |
| Avanos Medical | $24.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.68 | 2024 | Cyltezo |
| Roche Diagnostics Corporation | $19.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.96 | 2019 | |
| Daiichi Sankyo INC. | $17.11 | 2019 | |
| Therapeuticsmd, INC. | $16.97 | 2021 | |
| Myovant Sciences INC. | $13.92 | 2021 | |
| Allergan, INC. | $12.47 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $12.29 | 2019 | |
| Hologic Sales and Service, LLC | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.